Antibiogram St. Thomas-Elgin General Hospital

A Guide to Interpreting the Antibiogram

- The antibiogram is an annual cumulative report of the antimicrobial susceptibility rates of common pathogens recovered from patients receiving care at St. Thomas-Elgin General Hospital and is to be used as a resource to inform empirical antimicrobial therapy.
- Susceptibility rates are calculated from the compilation of susceptibility results from all 'first' clinical isolates of a specific pathogen recovered from an individual patient per 30-day period. The rationale for this referral period is based on the need to represent 'wild-type' susceptibility profiles and avoid over-representing antimicrobial resistance that may develop de novo during a patient's prolonged hospital stay.
- Susceptibility rates for pathogens or clinical scenarios represented by less than 30 isolates are not calculated due to their limited statistical significance and interpretive value.
- The appropriateness of empiric therapy is highlighted using a colour range that corresponds to susceptibility rates. Green, 80-100%; Yellow, 70-79%; Red, <70%.

2021 Antibiogram St. Thomas-Elgin General Hospital

Organism	Number of Isolates	Ampicillin	Amoxacillin-Clavulanate	Piperacillin-Tazobactam	Cloxacillin	Cephalexin (urinary tract)	Cefazolin	Ceftriaxone	Ceftazidime	Imipenem	Meropenem	Ciprofloxacin	Clindamycin	Doxycycline	Gentamicin	Tobramycin	TMP-SMX	Vancomycin
Escherichia coli	727	65	89			93	79	93		99		83			93	94	86	
Klebsiella pneumoniae complex	128		95			91	87	91		98		88			97	97	91	
Proteus mirabilis	46	96	98					98			100	98			96	96	96	
Enterobacter cloacae complex	47							68		100		96			96	96	94	
Klebsiella oxytoca	36		100					100		100		94			100	97	97	
Pseudomonas aeruginosa	108			91					87	81	93	89			95	98		
Staphylococcus aureus (incl. MRSA)	219				62								89	100			100	100
MRSA	84				0								94	100			100	100

Enterobacter, Citrobacter, Klebsiella aerogenes and *Serratia* species are intrinsically resistant to ampicillin, cefazolin, and cefuroxime and may develop resistance to broader-spectrum beta-lactams during prolonged beta-lactam therapy.